Applications across the
Microphysiological System Market span drug discovery, toxicology testing, disease modeling, and personalized medicine. Drug discovery represents the largest application segment, valued at USD 400 million in 2024 and projected to reach USD 1 billion by 2035. These systems streamline target validation and improve human response prediction, significantly reducing development timelines and costs.
Toxicology testing is experiencing steady expansion as regulatory agencies push for more reliable, human-relevant safety data. Disease modeling enables patient-specific studies of cancer, metabolic disorders, and neurodegenerative conditions. Personalized medicine applications are gaining traction by supporting tailored therapeutic strategies based on individual physiological responses.
TissUse secured a major contract with AstraZeneca in January 2025 to perform multi-organ safety and efficacy assessments, demonstrating commercial validation of these platforms. Contract research organizations increasingly adopt microphysiological systems to enhance service offerings and regulatory compliance.
FAQ
Q1: What is the largest application segment? A: Drug discovery is the leading application, expected to reach USD 1 billion by 2035.
Q2: How do these systems improve toxicology testing? A: They provide human-relevant data while reducing dependence on animal testing.
Q3: Which companies use these systems for drug development? A: AstraZeneca partners with TissUse for multi-organ safety assessments.
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Russian
Romaian
Portuguese (Brazil)
Greek